Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Liberty Global Sets Year-End Cash Target at $1.8 Billion

Liberty Global Sets Year-End Cash Target at $1.8 Billion

BitgetBitget2026/11/03 13:44
  • Liberty Global lowered its 2026 year-end cash target to $1.8 billion.
  • VMO2's planned £200 million shareholder distributions remain under review, with an update due in Q1 2027.
  • The joint venture forecasts total service revenue and adjusted EBITDA declines of 3%-5%, with adjusted free cash flow around £200 million.
  • VMO2 targets £800 million in annual run-rate cost savings by 2029, including roughly £300 million from lower people costs.
  • A further $100 million share buyback is anticipated in Q4 2026, following $100 million completed in Q3.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Liberty Global Ltd. published the original content used to generate this news brief on November 03, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss